Abduzhappar Gaipov1, Zhannat Taubaldiyeva2, Manarbek Askarov3, Zaiyrkhan Turebekov4, Larisa Kozina5, Askhat Myngbay6, Olga Ulyanova2, Saltanat Tuganbekova4. 1. Department of Extracorporeal Hemocorrection, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009. abduzhappar@gmail.com. 2. Department of Endocrinology, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009. 3. Department of Stem Cell Technology, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009. 4. Department of Internal Medicine, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009. 5. Department of Biochemistry, JSC National Scientific Medical Research Center, Avenue Abylai-Khan #42, Astana, Kazakhstan, 010009. 6. Private Institution "National Laboratory Astana", Nazarbayev University, Astana, Kazakhstan.
Abstract
BACKGROUND: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide. Previous studies demonstrated safety and efficacy of autologous bone marrow-derived mononuclear cells (ABM-MNCs) in induced type-1 diabetes mellitus (T1DM) rats. However, the effect of ABM-MNCs on urinary markers of DN in humans is not well studied. We evaluated the therapeutic effect of ABM-MNCs on the urinary markers microalbuminuria (MAU), urinary type-IV collagen and urinary neutrophil gelatinase-associated lipocalin (uNGAL) in T1DM patients with and without nephropathy. METHODS: This prospective open-label pilot study included 15 patients with T1DM, who had completed 2 visits within 6 months. Patients were divided into two groups according to the presence (DN, n = 7) and absence of nephropathy (T1DM, n = 8). ABM-MNCs were injected at each visit as per study protocol. Routine laboratory data, diabetes tests (fasting serum C-peptide and insulin, glycated hemoglobin, fasting and postprandial glucose), 24-h MAU and urinary type-IV collagen were measured at each visit. uNGAL levels were studied before and after 3 days of ABM-MNCs infusion at each visit. RESULTS: Mean age of patients was 29.2 ± 10.4 years, 33% were male, and 27% of the overall group had hypertension. MAU was significantly reduced in the overall group (- 26.0%, p = 0.037), including in DN (- 83.2%, p = 0.021). A short-term significant reduction of uNGAL levels was observed 3 days after ABM-MNCs administration during the both the 1st visit (median 13.4 vs. 9.5 ng/ml, p = 0.027) and 2nd visit (median 8.8 vs. 6.4 ng/ml, p = 0.042) in both groups. However this reduction did not remain significant at the 6-month follow-up. Urinary type-IV collagen did not respond significantly to ABM-MNCs infusion. CONCLUSION: Infusion of autologous bone marrow-derived mononuclear cells significantly reduced levels of MAU in DN patients. Further studies with larger sample size are needed to confirm these observations.
BACKGROUND:Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide. Previous studies demonstrated safety and efficacy of autologous bone marrow-derived mononuclear cells (ABM-MNCs) in induced type-1 diabetes mellitus (T1DM) rats. However, the effect of ABM-MNCs on urinary markers of DN in humans is not well studied. We evaluated the therapeutic effect of ABM-MNCs on the urinary markers microalbuminuria (MAU), urinary type-IV collagen and urinary neutrophil gelatinase-associated lipocalin (uNGAL) in T1DM patients with and without nephropathy. METHODS: This prospective open-label pilot study included 15 patients with T1DM, who had completed 2 visits within 6 months. Patients were divided into two groups according to the presence (DN, n = 7) and absence of nephropathy (T1DM, n = 8). ABM-MNCs were injected at each visit as per study protocol. Routine laboratory data, diabetes tests (fasting serum C-peptide and insulin, glycated hemoglobin, fasting and postprandial glucose), 24-h MAU and urinary type-IV collagen were measured at each visit. uNGAL levels were studied before and after 3 days of ABM-MNCs infusion at each visit. RESULTS: Mean age of patients was 29.2 ± 10.4 years, 33% were male, and 27% of the overall group had hypertension. MAU was significantly reduced in the overall group (- 26.0%, p = 0.037), including in DN (- 83.2%, p = 0.021). A short-term significant reduction of uNGAL levels was observed 3 days after ABM-MNCs administration during the both the 1st visit (median 13.4 vs. 9.5 ng/ml, p = 0.027) and 2nd visit (median 8.8 vs. 6.4 ng/ml, p = 0.042) in both groups. However this reduction did not remain significant at the 6-month follow-up. Urinary type-IV collagen did not respond significantly to ABM-MNCs infusion. CONCLUSION: Infusion of autologous bone marrow-derived mononuclear cells significantly reduced levels of MAU in DN patients. Further studies with larger sample size are needed to confirm these observations.
Authors: Kai M Schmidt-Ott; Kiyoshi Mori; Jau Yi Li; Avtandil Kalandadze; David J Cohen; Prasad Devarajan; Jonathan Barasch Journal: J Am Soc Nephrol Date: 2007-01-17 Impact factor: 10.121
Authors: H Okonogi; M Nishimura; Y Utsunomiya; K Hamaguchi; H Tsuchida; Y Miura; S Suzuki; T Kawamura; T Hosoya; K Yamada Journal: Clin Nephrol Date: 2001-05 Impact factor: 0.975
Authors: Fernando E Ezquer; Marcelo E Ezquer; Daniela B Parrau; Daniel Carpio; Alejandro J Yañez; Paulette A Conget Journal: Biol Blood Marrow Transplant Date: 2008-04-14 Impact factor: 5.742
Authors: Júlio C Voltarelli; Carlos E B Couri; Ana B P L Stracieri; Maria C Oliveira; Daniela A Moraes; Fabiano Pieroni; Marina Coutinho; Kelen C R Malmegrim; Maria C Foss-Freitas; Belinda P Simões; Milton C Foss; Elizabeth Squiers; Richard K Burt Journal: JAMA Date: 2007-04-11 Impact factor: 56.272